$HCTI
Healthcare Triangle, Inc. Stock $hcti

$hcti Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000160706223000255 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$8.526M	$9.838M	$11.06M
YoY Change	-26.42%	-11.02%	39.02%
Cost Of Revenue	$6.579M	$8.245M	$8.162M
YoY Change	-21.95%	1.02%	41.39%
Gross Profit	$1.947M	$1.593M	$2.894M
YoY Change	-38.37%	-44.96%	32.74%
Gross Profit Margin	22.84%	16.19%	26.18%
Selling, General & Admin	$2.638M	$3.389M	$3.091M
YoY Change	-14.96%	9.64%	60.31%
% of Gross Profit	135.49%	212.74%	106.81%
Research & Development	$102.0K	$539.0K	$1.066M
YoY Change	-84.21%	-49.44%	40.77%
% of Gross Profit	5.24%	33.84%	36.83%
Depreciation & Amortization	$802.0K	$874.0K	$711.0K
YoY Change	-4.98%	22.93%	237.53%
% of Gross Profit	41.19%	54.87%	24.57%
Operating Expenses	$3.542M	$4.802M	$4.868M
YoY Change	-22.87%	-1.36%	68.09%
Operating Profit	-$1.595M	-$3.209M	-$1.974M
YoY Change	11.3%	62.56%	175.73%
Interest Expense	-$186.0K	$62.00K	-$16.00K
YoY Change	-420.69%	-487.5%	-83.17%
% of Operating Profit
Other Income/Expense, Net	$0.00	$12.00K
YoY Change	-100.0%
Pretax Income	-$1.781M	-$3.259M	-$1.990M
YoY Change	340.84%	63.77%	145.37%
Income Tax	$5.000K	$19.00K	$21.00K
% Of Pretax Income
Net Earnings	-$1.786M	-$3.278M	-$2.011M
YoY Change	340.99%	63.0%	147.02%
Net Earnings / Revenue	-20.95%	-33.32%	-18.19%
Basic Earnings Per Share	-$0.42	-$0.79
Diluted Earnings Per Share	-$0.42	-$0.08	-$56.64K
COMMON SHARES
Basic Shares Outstanding	42.78M shares	41.71M shares
Diluted Shares Outstanding	4.273M shares	4.173M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$132.0K	$267.0K	$1.562M
YoY Change	-90.32%	-82.91%
Cash & Equivalents	$132.0K	$267.0K	$1.562M
Short-Term Investments
Other Short-Term Assets	$816.0K	$661.0K	$1.393M
YoY Change	22.16%	-52.55%
Inventory
Prepaid Expenses
Receivables	$4.476M	$5.512M	$6.739M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.424M	$6.440M	$9.694M
YoY Change	-36.77%	-33.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$57.00K	$67.00K	$219.0K
YoY Change	-29.63%	-69.41%
Goodwill	$1.289M	$1.289M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	-$1.000M
YoY Change
Total Long-Term Assets	$10.64M	$12.42M	$12.57M
YoY Change	-22.93%	-1.22%
TOTAL ASSETS
Total Short-Term Assets	$5.424M	$6.440M	$9.694M
Total Long-Term Assets	$10.64M	$12.42M	$12.57M
Total Assets	$16.07M	$18.86M	$22.27M
YoY Change	-28.23%	-15.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$926.0K	$1.307M	$1.577M
YoY Change	-27.09%	-17.12%
Accrued Expenses			$132.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$3.531M	$2.945M	$2.778M
YoY Change	9.93%	6.01%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.790M	$7.330M	$7.768M
YoY Change	-4.39%	-5.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.227M	$2.227M
YoY Change	0.0%
Total Long-Term Liabilities	$2.227M	$2.227M	$0.00
YoY Change	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.790M	$7.330M	$7.768M
Total Long-Term Liabilities	$2.227M	$2.227M	$0.00
Total Liabilities	$8.017M	$9.557M	$7.768M
YoY Change	-3.21%	23.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.63M	-$15.84M
YoY Change	247.09%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.051M	$9.303M	$14.50M
YoY Change
Total Liabilities & Shareholders Equity	$16.07M	$18.86M	$22.27M
YoY Change	-28.23%	-15.3%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.786M	-$3.278M	-$2.011M
YoY Change	340.99%	63.0%	147.02%
Depreciation, Depletion And Amortization	$802.0K	$874.0K	$711.0K
YoY Change	-4.98%	22.93%	237.53%
Cash From Operating Activities	-$1.221M	-$1.605M	$302.0K
YoY Change	-507.0%	-631.46%	-114.67%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$2.000K	-$20.00K
YoY Change	-100.0%	-110.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$2.000K	-$20.00K
YoY Change	-100.0%	-90.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.086M	$533.0K	-490.0K
YoY Change	-27.74%	-208.78%	-113.34%
NET CHANGE
Cash From Operating Activities	-1.221M	-$1.605M	302.0K
Cash From Investing Activities	0.000	-$2.000K	-20.00K
Cash From Financing Activities	1.086M	$533.0K	-490.0K
Net Change In Cash	-135.0K	-$1.074M	-208.0K
YoY Change	-32.16%	416.35%
FREE CASH FLOW
Cash From Operating Activities	-$1.221M	-$1.605M	$302.0K
Capital Expenditures	$0.00	$2.000K	-$20.00K
Free Cash Flow	-$1.221M	-$1.607M	$322.0K
YoY Change	-153.04%	-599.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	816000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	6440000	usd
CY2023Q1	dei	City Area Code CityAreaCode	(925)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	270-4812
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	HCTI
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42778762	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	267000	usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001839285
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Short Term Lease Payments ShortTermLeasePayments		usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022Q1	us-gaap	Other Noncash Income OtherNoncashIncome		usd
CY2023Q1	HCTI	Business Combination Working Capital BusinessCombinationWorkingCapital		usd
CY2023Q1	HCTI	Deferredtaxassetnetofvaluationallowance Deferredtaxassetnetofvaluationallowance		usd
CY2022Q4	HCTI	Deferredtaxassetnetofvaluationallowance Deferredtaxassetnetofvaluationallowance		usd
CY2023Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023Q1	HCTI	Current Federal Tax Expense Benefits CurrentFederalTaxExpenseBenefits		usd
CY2022Q1	HCTI	Current Federal Tax Expense Benefits CurrentFederalTaxExpenseBenefits		usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40903
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE TRIANGLE, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3559776
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7901 Stoneridge Drive
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 220
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Pleasanton
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94588
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1341000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5512000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5592000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	661000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	7749000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	539000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	67000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9713000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10570000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	1289000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1289000	usd
CY2023Q1	HCTI	Dues From Affiliates DuesFromAffiliates	1351000	usd
CY2022Q4	HCTI	Dues From Affiliates DuesFromAffiliates	1075000	usd
CY2023Q1	us-gaap	Assets Assets	18860000	usd
CY2022Q4	us-gaap	Assets Assets	20763000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1307000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1481000	usd
CY2023Q1	HCTI	Warrant Liability WarrantLiability	55000	usd
CY2022Q4	HCTI	Warrant Liability WarrantLiability	55000	usd
CY2023Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	2945000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	2412000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3023000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2200000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7330000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6148000	usd
CY2023Q1	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2227000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2227000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	9557000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8375000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	HCTI	Preferred Stock Voting Shares PreferredStockVotingShares	6000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41859531	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41709531	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25146000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24956000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15843000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12568000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9303000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12388000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18860000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20763000	usd
CY2023Q1	us-gaap	Revenues Revenues	9838000	usd
CY2022Q1	us-gaap	Revenues Revenues	11056000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	8245000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	8162000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1066000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-155000	usd
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1761000	usd
CY2022Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1740000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1628000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1351000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	874000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	711000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4802000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	4868000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3209000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1974000	usd
CY2023Q1	us-gaap	Other Income OtherIncome	12000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-62000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-16000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3259000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1990000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3278000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2011000	usd
CY2023Q1	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-0.078
CY2022Q1	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-0.057
CY2023Q1	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	41859531	shares
CY2022Q1	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	35507184	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16135000	usd
CY2022Q1	HCTI	Issue Of Options Isonso IssueOfOptionsIsonso	15000	usd
CY2022Q1	HCTI	Cash Collected On Isonso CashCollectedOnIsonso	10000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	350000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-2011000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	14499000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12388000	usd
CY2023Q1	HCTI	Issue Of Options Isonso IssueOfOptionsIsonso	142000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	51000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3278000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9303000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3278000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2011000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	874000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	711000	usd
CY2023Q1	HCTI	Common Stock Issued For Services CommonStockIssuedForServices	51000	usd
CY2022Q1	HCTI	Common Stock Issued For Services CommonStockIssuedForServices	350000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	139000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-80000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2933000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1031000	usd
CY2023Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	276000	usd
CY2022Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	451000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-174000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-295000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	824000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	130000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1605000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	351000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	2000	usd
CY2022Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	20000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10000	usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	533000	usd
CY2022Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	-500000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	49000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	533000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-539000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1074000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-208000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1341000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1770000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	267000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1562000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	62000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	16000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	19000	usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	21000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zqUoW3NNExE8" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span id="xdx_86C_zZfUNK8pNKnc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements is in conformity with GAAP which requires us to make estimates, judgments and assumptions that affect the financial statements and the notes thereto. These estimates are based on information available as of the date of the financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the standalone selling price for each distinct performance obligation</span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the determination of the period of benefit for amortization of deferred costs.</span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 7px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the fair value of assets acquired, and liabilities assumed for business combinations.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation including warrants</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"/>
CY2023Q1	HCTI	Net Income Loss Before Income Tax Expenses Amount Changes NetIncomeLossBeforeIncomeTaxExpensesAmountChanges	-1269000	usd
CY2023Q1	HCTI	Interest Expense Percentage Changes InterestExpensePercentageChanges	-2.88	pure
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3259000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9838000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11056000	usd
CY2023Q1	HCTI	Changes Amount ChangesAmount	-1218000	usd
CY2023Q1	HCTI	Changes Percentage ChangesPercentage	-0.11	pure
CY2023Q1	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	-1046000	usd
CY2022Q1	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	483000	usd
CY2023Q1	HCTI	Total Segment Operating Profit Amount Changes TotalSegmentOperatingProfitAmountChanges	-1529000	usd
CY2023Q1	HCTI	Total Segment Operating Profit Percentage Changes TotalSegmentOperatingProfitPercentageChanges	-3.17	pure
CY2023Q1	HCTI	Unallocated Costs UnallocatedCosts	2163000	usd
CY2022Q1	HCTI	Unallocated Costs UnallocatedCosts	2457000	usd
CY2023Q1	HCTI	Less Unallocated Costs Amount Changes LessUnallocatedCostsAmountChanges	-294000	usd
CY2023Q1	HCTI	Less Unallocated Costs Percentage Changes LessUnallocatedCostsPercentageChanges	-0.12	pure
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3209000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1974000	usd
CY2023Q1	HCTI	Income From Operations Amount Changes IncomeFromOperationsAmountChanges	-1235000	usd
CY2023Q1	HCTI	Income From Operations Percentage Changes IncomeFromOperationsPercentageChanges	-0.63	pure
CY2023Q1	us-gaap	Other Noncash Income OtherNoncashIncome	12000	usd
CY2023Q1	HCTI	Other Income Amount Changes OtherIncomeAmountChanges	12000	usd
CY2023Q1	HCTI	Other Income Percentage Changes OtherIncomePercentageChanges	-1	pure
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	62000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	16000	usd
CY2023Q1	HCTI	Interest Expense Amount Changes InterestExpenseAmountChanges	-46000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1990000	usd
CY2023Q1	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	2945000	usd
CY2023Q1	HCTI	Net Income Loss Before Income Tax Expenses Percentage Changes NetIncomeLossBeforeIncomeTaxExpensesPercentageChanges	-0.64	pure
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	5512000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5592000	usd
CY2023Q1	HCTI	Warrant Liabilities WarrantLiabilities	55000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2227000	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	2412000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_z910UOUjIZC3" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span id="xdx_86E_zkuyEKOxTUZ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and trade receivables. Credit risks associated with trade receivables is minimal due to the Company’s customer base which consist of large customer base and ongoing procedures, which monitor the credit worthiness of its customers. For the quarter ended March 31, 2023 and 2022 revenue from the top five customers accounted for approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_ze2n61x8ps1l">80</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zkOcz9KbGkL7">76</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of total revenue respectively. For the quarter ended March 31, 2023 and year ended December 31, 2022 accounts receivable from five major customers accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zwnbtlO6Jyr8">82</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zt7nwu1anDkk">72</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the total accounts receivables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances in various financial institutions. The balances are generally insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20230331_z3tZf4mZzIH1">250,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(valid through March 31, 2023) per institution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023 and December 31, 2022, the Company had Nil<span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_c20230331_zUlRY1RaC4P4" style="color: White">0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_c20221231_z3CndSZMdure">816 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively, of uninsured cash balances. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.</span></p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	816000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	123000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	119000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	56000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	67000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	17000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	8000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16473000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6760000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9713000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16473000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5903000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10570000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	857000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	660000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	1251000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	2114000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	2114000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	2114000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	2114000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	6000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9713000	usd
CY2023Q1	HCTI	Due From Other Related Party Noncurrent DueFromOtherRelatedPartyNoncurrent	3190000	usd
CY2022Q1	HCTI	Due From Other Related Party Noncurrent DueFromOtherRelatedPartyNoncurrent	2091000	usd
CY2023Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	67000	usd
CY2022Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	49000	usd
CY2023Q1	HCTI	Due From Related Party DueFromRelatedParty	12000	usd
CY2022Q1	HCTI	Due From Related Party DueFromRelatedParty	131000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	4500000	usd
CY2023Q1	HCTI	Weighted Average Price Of Stock Amount WeightedAveragePriceOfStockAmount	700000	usd
CY2023Q1	HCTI	Unvested Common Stock UnvestedCommonStock	83718	shares
CY2023Q1	HCTI	Earnout Payment EarnoutPayment	2500000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2209000	usd
CY2023Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-04-30
CY2023Q1	us-gaap	Goodwill Gross GoodwillGross	1289000	usd
CY2022Q1	HCTI	Weighted Average Shares Outstanding Used In Basic Per Common Share Computations WeightedAverageSharesOutstandingUsedInBasicPerCommonShareComputations	35507184	shares
CY2023Q1	HCTI	Weighted Average Basic Diluted Eps WeightedAverageBasicDilutedEps	-0.078	shares
CY2023Q1	HCTI	Estimated Fair Value Of Common Stock Warrant EstimatedFairValueOfCommonStockWarrant	0.40
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	2.88
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	6018000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	1289000	usd
CY2023Q1	us-gaap	Cash Cash	970000	usd
CY2023Q1	HCTI	Business Combination Acquisition Accounts Receivables BusinessCombinationAcquisitionAccountsReceivables	3142000	usd
CY2023Q1	HCTI	Business Combination Acquisition Other Assets Current BusinessCombinationAcquisitionOtherAssetsCurrent	11419000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	758000	usd
CY2023Q1	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	2209000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	679000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	3646000	usd
CY2023Q1	HCTI	Net Working Capital Acquired NetWorkingCapitalAcquired	7773000	usd
CY2023Q1	HCTI	Total Business Acquisitions Purchase Price TotalBusinessAcquisitionsPurchasePrice	7773000	usd
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.88
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	55000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.01	pure
CY2022Q1	HCTI	Weighted Average Basic Diluted Eps WeightedAverageBasicDilutedEps	-0.057	shares
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	880000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2578000	usd
CY2023Q1	HCTI	Stockbased Compensation StockbasedCompensation	-38000	usd
CY2022Q4	HCTI	Stockbased Compensation StockbasedCompensation	-27000	usd
CY2022Q4	HCTI	Other Income Loan Forgiveness OtherIncomeLoanForgiveness	292000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	842000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2843000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	842000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2843000	usd
CY2023Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	19000	usd
CY2022Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	21000	usd
CY2023Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	19000	usd
CY2022Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	21000	usd
CY2023Q1	HCTI	Total Income Expenses Benefit TotalIncomeExpensesBenefit	19000	usd
CY2022Q1	HCTI	Total Income Expenses Benefit TotalIncomeExpensesBenefit	21000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2085136	shares
CY2023Q1	HCTI	Incentive Stock Options Iso IncentiveStockOptionsIso	2000000	shares
CY2023Q1	HCTI	Nonqualified Stock Options Nso NonqualifiedStockOptionsNso	880757	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	123864	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3328243	shares
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	377000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3278000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2011000	usd
CY2023Q1	HCTI	Weighted Average Shares Outstanding Used In Basic Per Common Share Computations WeightedAverageSharesOutstandingUsedInBasicPerCommonShareComputations	41859531	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
hcti-20230331_cal.xml	Edgar Link	unprocessable
hcti-20230331_def.xml	Edgar Link	unprocessable
0001607062-23-000255-index-headers.html	Edgar Link	pending
0001607062-23-000255-index.html	Edgar Link	pending
0001607062-23-000255.txt	Edgar Link	pending
0001607062-23-000255-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hcti-20230331.xsd	Edgar Link	pending
hcti033123form10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
hcti-20230331_lab.xml	Edgar Link	unprocessable
hcti-20230331_pre.xml	Edgar Link	unprocessable
hcti033123form10q_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCTI
Healthcare Triangle, Inc. Stock $hcti

2023 Q2 Form 10-Q Financial Statement

#000160706223000255 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI Healthcare Triangle, Inc. Stock $hcti

2023 Q2 Form 10-Q Financial Statement

#000160706223000255 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI
Healthcare Triangle, Inc. Stock $hcti